Posted by JohnX2 on March 1, 2002, at 19:03:13
In reply to When is duloxetine to be approved?, posted by SLS on March 1, 2002, at 9:48:21
Hi Scott,I haven't heard much about Duloxetine approval,
but I'll dig around tonight.So what's the status of your Effexor trial? You didn't sound
too upbeat in your earlier post. :(I'm curious what the current thinking is of
your treating physicians? I.E. what rationale
do they have for going direction A vs. direction B ?
Just wondering.I was reading an interesting article in
regards to treatment resistant mood disorders
thinking in terms of my own poop out syndrome:
http://www.acnp.org/g4/GN401000110/Default.htm
It suggested using a calcium channel blocker
such as nimodipine. This blocks calcium flux
through NMDA channels. An nmda antagonist like
memantine would work as well I believe.Btw, have you been reevaluated as a DST
non-suppressor?Sorry I'm so nosy. I'm just curious what the current
indicators are as to why your medicines would not be
kicking in (I'm sure you got me beat on this one).Best Wishes Always,
John> Hi.
>
> Here's something I thought I'd pass along from Medscape...
>
>
>
> 1. Duloxetine Significantly Reduces Symptoms of Depression
>
> http://www.medscape.com/viewarticle/411151
>
>
> From the verbiage used, it appears that duloxetine is similar to venlafaxine, not only with respect to the combined actions of the reuptake inhibition of both NE and 5-HT, but also with respect to efficacy in treating depression. Venlafaxine gets more people well and produces a greater degree of improvement than any of the SSRIs. These conclusions regarding venlafaxine are derived from a study involving over 2000 patients. That duloxetine showed itself to be superior to paroxetine in the studies referred to here indicates that both of these NE/5-HT reuptake inhibitors are superior to the SSRIs. I remember Andrew Nierenberg telling me in 1992 that venlafaxine was sort of a non-MAOI MAOI. Perhaps duloxetine will be as well. I might put off switching to Nardil from Effexor if approval of duloxetine is imminent.
>
> Does anyone know how close duloxetine is to reaching market?
>
>
> - Scott
>
>
> ----------------------------------------------
>
>
> <excerpts>
>
>
> "NEW YORK (MedscapeWire) Nov 26 — Data on duloxetine, an
> investigational balanced serotonin and norepinephrine reuptake
> inhibitor, suggest it is more effective than placebo and paroxetine
> in reducing depressive symptoms. In addition, duloxetine was found
> to be more effective than placebo in reducing the physical symptoms
> associated with depression. The data were presented at the 14th
> Annual US Psychiatric and Mental Health Congress in Boston,
> Massachusetts."
>
> "The studies also suggest that duloxetine provides balanced, potent,
> and tolerable effect at all doses, though the therapeutic evidence
> of duloxetine 60 mg/once daily dose was similar in magnitude to
> duloxetine 40 mg/taken twice a day (80 mg), indicating that a 60
> mg/once daily dosing regimen can be used. The data were measured by
> mean change on the 17-item Hamilton Depression Rating Scale
> (HAMD17)."
>
> "Duloxetine's dual mechanism of action offers the possibility for
> rapid onset of antidepressant effect, better response with pain
> symptoms, and higher remission rates than available with SSRIs that
> are most commonly prescribed today," said John H. Greist, MD,
> clinical professor of psychiatry, University of Wisconsin Medical
> School, who presented data on duloxetine at the Congress. "Because
> we recognize that serotonin blockade alone is not sufficient for
> everyone, and that physical symptoms of depression often go
> unresolved, duloxetine may become a potent first-line
> antidepressant therapy."
>
>
> ----------------------------------------------
poster:JohnX2
thread:95939
URL: http://www.dr-bob.org/babble/20020301/msgs/95990.html